Abbott has received CE mark approval for its Libre Duo and Libre Duo 10 Day systems, becoming the first company to bring dual glucose-ketone monitoring devices to the diabetes market.

The wearable systems are designed to continuously monitor both glucose and ketone levels every minute, enabling patients with type 1 and type 2 diabetes to receive early warning signs of diabetic ketoacidosis (DKA), a potentially life-threatening complication that traditionally requires blood or urine testing for detection.

The newly approved devices integrate with Abbott’s Libre digital health ecosystem, which includes its continuous glucose monitoring (CGM) platforms, smartphone applications, and cloud-based reporting systems. 

Libre Duo is approved for up to 15 days of wear in adults, while Libre Duo 10 Day can be used for up to 10 days in individuals aged two years and older. Abbott plans to commercially launch the devices across select European markets later this year.

The systems are also currently under review by the US Food and Drug Administration. During the company’s Q1 earnings update, Abbott CEO Robert Ford indicated that regulatory approval in the United States is expected in the second half of 2026.

Chris Scoggins, Executive Vice-President of Abbott’s diabetes care business, said people living with diabetes often face constant anxiety around severe complications. He noted that the Libre Duo systems are designed to provide earlier and clearer insights, helping patients, families, and healthcare providers respond before conditions worsen.